ストックスクリーナーアプリを入手
114.22
109.08%
59.59
アフターアワーズ：
115.75
1.53
+1.34%
Corcept Therapeutics Inc (CORT) 最新ニュース
Corcept looks to NDA following strong phase III ovarian cancer data - BioWorld MedTech
Corcept’s Relacorilant Shows Benefit In Ovarian Cancer, Expanding Pipeline Opportunity - insights.citeline.com
Deep Dive Into Corcept Therapeutics Stock: Analyst Perspectives (7 Ratings) - Benzinga
Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast - Benzinga
Why Is Corcept (CORT) Stock Soaring Today - Yahoo Finance
Corcept’s ovarian cancer drug cuts disease progression in study, shares jump By Reuters - Investing.com
Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip - simplywall.st
Corcept's ovarian cancer drug cuts disease progression in study, shares jump - Reuters
NewsMax, Celsius Holdings, Corcept Therapeutics: Market Minute - Yahoo Finance
Corcept shares soar after Phase 3 win in platinum-resistant ovarian cancer - Endpoints News
Corcept Therapeutics's Options Frenzy: What You Need to Know - Benzinga
Corcept Therapeutics shares surge on positive late-stage ovarian cancer trial results - Proactive Investors
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet - Benzinga
Yum Brands, Corcept Therapeutics, Hut 8: Trending tickers - Yahoo Finance
Market movers: Mr Cooper, Newsmax, Corcept Therapeutics... - Proactive financial news
HC Wainwright Adjusts Price Target on Corcept Therapeutics to $150 From $115, Maintains Buy Rating - MarketScreener
Corcept Therapeutics stock soars to all-time high of $95.42 - Investing.com
Corcept soars as ovarian cancer drug succeeds late-stage trial - TradingView
Sector Update: Health Care - TradingView
Corcept Therapeutics' Ovarian Cancer Therapy Meets Main Goal in Phase 3 Study; Shares Jump - Marketscreener.com
Corcept's ovarian cancer drug meets main goal in late-stage study, shares jump - TradingView
Corcept Therapeutics stock soars after successful Phase 3 trial - Investing.com
Corcept Therapeutics stock soars after successful Phase 3 trial By Investing.com - Investing.com UK
Corcept Therapeutics Says Primary Endpoint Met in Phase 3 Ovarian Cancer Drug Study; Shares Up Pre-Bell - MarketScreener
Corcept's ovarian cancer combination drug meets main goal in late-stage study - TradingView
Corcept reports key trial success in ovarian cancer treatment - Investing.com
Major Clinical Trial Success: New Ovarian Cancer Drug Shows 4.5-Month Survival Advantage - Stock Titan
Did Corcept Therapeutics Incorporated Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky InvestigateCORT - ACCESS Newswire
NewMax goes public, Corcept Therapeutics gains, Moderna under pressure - Yahoo Finance
Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report? - Yahoo Finance
Corcept Therapeutics president Sean Maduck sells $102,804 in stock By Investing.com - Investing.com South Africa
Corcept therapeutics officer sells shares worth $25,504 - Investing.com India
Corcept therapeutics CEO Joseph Belanoff sells $120k in stock - Investing.com India
Corcept Therapeutics president Sean Maduck sells $102,804 in stock - Investing.com
3 Reasons to Sell CORT and 1 Stock to Buy Instead - Yahoo Finance
Avantax Advisory Services Inc. Invests $293,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Global Cushing's Syndrome Treatment Market: Research & - openPR
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stake Raised by Natixis Advisors LLC - Defense World
Cushing's Syndrome Pipeline 2025: Therapies, MOA Insights, - openPR
Research Analysts Offer Predictions for CORT Q1 Earnings - Defense World
Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year? - Yahoo
Raymond James Financial Inc. Makes New $12.08 Million Investment in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Proficio Capital Partners LLC Takes $1.60 Million Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Shareholders that lost money on Corcept Therapeutics Incorporated(CORT) should contact Levi & Korsinsky about Securities Fraud InvestigationCORT - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics IncorporatedCORT - PR Newswire
Victory Capital Management Inc. Increases Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Charles Schwab Investment Management Inc. Acquires 25,073 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
M&T Bank Corp Sells 1,249 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Armenian Reporter
Corcept therapeutics director sells $117,920 in stock - Investing.com India
Corcept therapeutics director sells $117,920 in stock By Investing.com - Investing.com South Africa
Corcept trial to evaluate Cushing’s and hypertension - Cushing's Disease News
Head-To-Head Review: Corcept Therapeutics (NASDAQ:CORT) vs. Ocular Therapeutix (NASDAQ:OCUL) - Defense World
NVO Stock Down 9% as CagriSema Misses Target in Second Obesity Study - TradingView
Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Shareholders to Inquire about Securities Investigation - Markets Insider
Before You Invest, Make Sure You Check This Corcept Therapeutics Inc (NASDAQ: CORT) Analysis - Stocks Register
Corcept Therapeutics Stock Surges Amid Clinical Trial News - TipRanks
Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Shareholders to Connect - Markets Insider
Corcept Therapeutics launches study on link between high cortisol and resistant hypertension - Marketscreener.com
Corcept Therapeutics initiates Momentum trial to treat resistant hypertension - TipRanks
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension - Business Wire
Bank of New York Mellon Corp Has $29.72 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):